| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.008 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.9 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |